These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33962771)

  • 1. Tacrolimus Immunosuppression Causes Drug-Induced Hypersensitivity Reactions in Liver-Transplant Patients: A 3-Case Report.
    Mavroudi A; Imvrios G; Xinias I; Cassimos D; Vagiotas L; Giouleme O
    Transplant Proc; 2021 Jun; 53(5):1731-1735. PubMed ID: 33962771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients.
    Altieri M; Delaval G; Kimmoun E; Allaire M; Salamé E; Dumortier J
    Exp Clin Transplant; 2018 Jun; 16(3):321-325. PubMed ID: 28697715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of tacrolimus-associated food allergy after liver transplantation.
    Obayashi N; Suzuki M; Yokokura T; Naritaka N; Nakano S; Ohtsuka Y; Sugo H; Kawasaki S; Shimizu T
    Pediatr Int; 2015 Dec; 57(6):1205-7. PubMed ID: 26541649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation.
    Iaria G; Sforza D; Angelico R; Toti L; de Luca L; Manuelli M; Bellini I; Manzia TM; Anselmo A; Tisone G
    Transplant Proc; 2011 May; 43(4):1028-9. PubMed ID: 21620043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant food allergy in children is associated with liver and not with renal transplantation: a monocentric comparative study.
    De Bruyne R; Dullaers M; Van Biervliet S; Vande Velde S; Raes A; Gevaert P; Van Winckel M
    Eur J Pediatr; 2013 Aug; 172(8):1069-75. PubMed ID: 23609525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment.
    Ma MK; Kwan LP; Mok MM; Yap DY; Tang CS; Chan TM
    Ren Fail; 2013 Aug; 35(7):942-5. PubMed ID: 23815459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression.
    Lykavieris P; Frauger E; Habes D; Bernard O; Debray D
    Transplantation; 2003 Jan; 75(1):152-55. PubMed ID: 12544888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergic sensitization in kidney-transplanted patients prevails under tacrolimus treatment.
    Gruber S; Tiringer K; Dehlink E; Eiwegger T; Mayer E; Konstantin H; Kikic Z; Graf A; Szépfalusi Z
    Clin Exp Allergy; 2011 Aug; 41(8):1125-32. PubMed ID: 21545550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation.
    Trautmann A; Brockow K; Behle V; Stoevesandt J
    J Allergy Clin Immunol Pract; 2019; 7(7):2218-2224. PubMed ID: 30980898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study.
    Lladó L; González-Castillo A; Fabregat J; Baliellas C; Ramos E; González-Vilatarsana E; Busquets J; Xiol X
    Ann Transplant; 2019 Jan; 24():36-44. PubMed ID: 30655498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study.
    Adam R; Karam V; Cailliez V; Trunečka P; Samuel D; Tisone G; Němec P; Soubrane O; Schneeberger S; Gridelli B; Bechstein WO; Risaliti A; Line PD; Vivarelli M; Rossi M; Pirenne J; Klempnauer JL; Rummo A; Di Benedetto F; Zieniewicz K; Troisi R; Paul A; Vali T; Kollmar O; Boudjema K; Hoti E; Colledan M; Pratschke J; Lang H; Popescu I; Ericzon BG; Strupas K; De Simone P; Kochs E; Heyd B; Gugenheim J; Pinna AD; Bennet W; Kazimi M; Bachellier P; Wigmore SJ; Rasmussen A; Clavien PA; Hidalgo E; O'Grady JG; Zamboni F; Kilic M; Duvoux C;
    Transplantation; 2019 Sep; 103(9):1844-1862. PubMed ID: 31343568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alcohol-induced rash caused by topical tacrolimus.
    Knight AK; Boxer M; Chandler MJ
    Ann Allergy Asthma Immunol; 2005 Sep; 95(3):291-2. PubMed ID: 16200821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized reactions during skin testing with clindamycin in drug hypersensitivity: a report of 3 cases and review of the literature.
    Papakonstantinou E; Müller S; Röhrbein JH; Wieczorek D; Kapp A; Jakob T; Wedi B
    Contact Dermatitis; 2018 Apr; 78(4):274-280. PubMed ID: 29356000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge.
    Jannot M; Masson I; Alamartine E; Mariat C
    Ann Transplant; 2014 Jul; 19():320-4. PubMed ID: 24999809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.